Concepts (291)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tissue Scaffolds | 13 | 2016 | 111 | 3.090 |
Why?
|
| Tissue Engineering | 15 | 2018 | 212 | 2.280 |
Why?
|
| Elastin | 20 | 2016 | 116 | 2.260 |
Why?
|
| Collagen | 17 | 2016 | 636 | 1.760 |
Why?
|
| Heart Valve Prosthesis | 16 | 2020 | 222 | 1.630 |
Why?
|
| Blood Vessel Prosthesis | 5 | 2015 | 182 | 1.450 |
Why?
|
| Bioprosthesis | 14 | 2018 | 101 | 1.350 |
Why?
|
| Heart Valves | 6 | 2018 | 171 | 1.270 |
Why?
|
| Intervertebral Disc | 3 | 2014 | 51 | 1.260 |
Why?
|
| Extracellular Matrix | 11 | 2021 | 493 | 1.230 |
Why?
|
| Glycosaminoglycans | 7 | 2014 | 88 | 1.070 |
Why?
|
| Biocompatible Materials | 12 | 2013 | 247 | 1.060 |
Why?
|
| Aortic Valve | 8 | 2021 | 249 | 1.020 |
Why?
|
| Regeneration | 2 | 2014 | 105 | 0.870 |
Why?
|
| Stem Cells | 6 | 2020 | 248 | 0.800 |
Why?
|
| Hydrolyzable Tannins | 6 | 2018 | 25 | 0.790 |
Why?
|
| Aortic Diseases | 2 | 2021 | 113 | 0.790 |
Why?
|
| Aorta | 5 | 2015 | 316 | 0.760 |
Why?
|
| Calcinosis | 10 | 2018 | 241 | 0.740 |
Why?
|
| Materials Testing | 6 | 2013 | 263 | 0.720 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2021 | 134 | 0.700 |
Why?
|
| Swine | 17 | 2018 | 672 | 0.690 |
Why?
|
| Glutaral | 13 | 2007 | 41 | 0.670 |
Why?
|
| Cross-Linking Reagents | 5 | 2014 | 80 | 0.660 |
Why?
|
| Heart Valve Diseases | 4 | 2021 | 123 | 0.640 |
Why?
|
| Animals | 46 | 2021 | 20877 | 0.600 |
Why?
|
| Sus scrofa | 6 | 2014 | 74 | 0.550 |
Why?
|
| Arteries | 2 | 2014 | 108 | 0.530 |
Why?
|
| Mammary Arteries | 1 | 2014 | 18 | 0.510 |
Why?
|
| Rats | 23 | 2018 | 5300 | 0.500 |
Why?
|
| Vascular Grafting | 1 | 2014 | 12 | 0.490 |
Why?
|
| Absorbable Implants | 1 | 2014 | 29 | 0.480 |
Why?
|
| Femoral Artery | 1 | 2014 | 139 | 0.480 |
Why?
|
| Hydrogels | 1 | 2014 | 54 | 0.470 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2013 | 17 | 0.450 |
Why?
|
| Microvessels | 1 | 2013 | 43 | 0.440 |
Why?
|
| Immunohistochemistry | 8 | 2018 | 1174 | 0.430 |
Why?
|
| Myocardium | 3 | 2013 | 1204 | 0.420 |
Why?
|
| Phenols | 2 | 2009 | 73 | 0.410 |
Why?
|
| Cell Differentiation | 3 | 2013 | 1034 | 0.410 |
Why?
|
| Models, Biological | 2 | 2014 | 981 | 0.410 |
Why?
|
| Flavonoids | 2 | 2009 | 109 | 0.410 |
Why?
|
| Matrix Metalloproteinases | 4 | 2013 | 223 | 0.400 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2020 | 195 | 0.400 |
Why?
|
| Spinal Cord Regeneration | 1 | 2010 | 3 | 0.390 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2020 | 164 | 0.390 |
Why?
|
| Biomimetic Materials | 1 | 2010 | 20 | 0.390 |
Why?
|
| Spheroids, Cellular | 3 | 2014 | 45 | 0.360 |
Why?
|
| Rats, Sprague-Dawley | 13 | 2013 | 2083 | 0.360 |
Why?
|
| Mitral Valve | 4 | 2020 | 166 | 0.350 |
Why?
|
| Pericardium | 4 | 2010 | 97 | 0.320 |
Why?
|
| Myocytes, Smooth Muscle | 4 | 2014 | 144 | 0.290 |
Why?
|
| Tissue Preservation | 2 | 2005 | 44 | 0.290 |
Why?
|
| Magnetite Nanoparticles | 3 | 2014 | 28 | 0.280 |
Why?
|
| Cattle | 9 | 2014 | 475 | 0.270 |
Why?
|
| Calcium | 8 | 2009 | 929 | 0.260 |
Why?
|
| Biomechanical Phenomena | 4 | 2014 | 368 | 0.250 |
Why?
|
| Disease Models, Animal | 9 | 2020 | 2550 | 0.230 |
Why?
|
| Adipose Tissue | 3 | 2016 | 221 | 0.230 |
Why?
|
| Cells, Cultured | 9 | 2020 | 2673 | 0.220 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2018 | 139 | 0.220 |
Why?
|
| Aorta, Abdominal | 3 | 2015 | 97 | 0.210 |
Why?
|
| Tannins | 3 | 2006 | 17 | 0.200 |
Why?
|
| Hematoma | 1 | 2021 | 47 | 0.190 |
Why?
|
| Atherosclerosis | 2 | 2021 | 204 | 0.190 |
Why?
|
| Fixatives | 5 | 2006 | 24 | 0.190 |
Why?
|
| Water | 2 | 2013 | 228 | 0.190 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2020 | 36 | 0.190 |
Why?
|
| Pulmonary Valve | 1 | 2020 | 40 | 0.190 |
Why?
|
| Osteogenesis | 4 | 2019 | 152 | 0.190 |
Why?
|
| Integrin alpha4beta1 | 1 | 2020 | 3 | 0.190 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2020 | 15 | 0.180 |
Why?
|
| DNA | 3 | 2013 | 597 | 0.180 |
Why?
|
| Streptozocin | 1 | 2020 | 34 | 0.180 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2020 | 15 | 0.180 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2020 | 99 | 0.180 |
Why?
|
| Diabetes Complications | 1 | 2021 | 249 | 0.180 |
Why?
|
| Humans | 19 | 2021 | 68525 | 0.180 |
Why?
|
| Dyslipidemias | 1 | 2020 | 98 | 0.170 |
Why?
|
| Detergents | 1 | 2018 | 34 | 0.160 |
Why?
|
| Bone Marrow Cells | 2 | 2010 | 217 | 0.160 |
Why?
|
| Cardiac Catheterization | 1 | 2020 | 419 | 0.160 |
Why?
|
| Cell Survival | 4 | 2013 | 901 | 0.150 |
Why?
|
| Magnetic Phenomena | 2 | 2013 | 12 | 0.150 |
Why?
|
| Matrix Metalloproteinase 2 | 6 | 2010 | 145 | 0.150 |
Why?
|
| Nanostructures | 2 | 2010 | 112 | 0.150 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 236 | 0.140 |
Why?
|
| Male | 16 | 2020 | 37281 | 0.140 |
Why?
|
| Porosity | 2 | 2013 | 63 | 0.140 |
Why?
|
| Printing, Three-Dimensional | 1 | 2015 | 31 | 0.140 |
Why?
|
| Aortography | 1 | 2015 | 72 | 0.130 |
Why?
|
| Hyaluronoglucosaminidase | 2 | 2007 | 43 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 693 | 0.130 |
Why?
|
| Prosthesis Design | 2 | 2015 | 301 | 0.130 |
Why?
|
| Computer-Aided Design | 1 | 2015 | 101 | 0.130 |
Why?
|
| Matrix Metalloproteinase 9 | 5 | 2010 | 160 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2019 | 529 | 0.130 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2014 | 317 | 0.130 |
Why?
|
| Endothelium | 1 | 2014 | 98 | 0.120 |
Why?
|
| Implants, Experimental | 1 | 2014 | 15 | 0.120 |
Why?
|
| Capillaries | 1 | 2014 | 105 | 0.120 |
Why?
|
| Perfusion | 1 | 2014 | 131 | 0.120 |
Why?
|
| Fibroblasts | 6 | 2013 | 902 | 0.120 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 186 | 0.120 |
Why?
|
| RNA, Messenger | 4 | 2013 | 1663 | 0.120 |
Why?
|
| Tissue Fixation | 2 | 2004 | 58 | 0.120 |
Why?
|
| Prosthesis Failure | 3 | 2003 | 130 | 0.120 |
Why?
|
| Models, Cardiovascular | 3 | 2003 | 133 | 0.120 |
Why?
|
| Heparin | 1 | 2014 | 205 | 0.110 |
Why?
|
| Rats, Wistar | 1 | 2014 | 371 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 710 | 0.110 |
Why?
|
| Peptide Hydrolases | 1 | 1993 | 82 | 0.110 |
Why?
|
| Hydroxyproline | 1 | 2013 | 33 | 0.110 |
Why?
|
| Basement Membrane | 1 | 2013 | 48 | 0.110 |
Why?
|
| Elastic Modulus | 1 | 2013 | 25 | 0.110 |
Why?
|
| Time Factors | 6 | 2019 | 4655 | 0.110 |
Why?
|
| Vascular Patency | 1 | 2013 | 122 | 0.110 |
Why?
|
| Fibronectins | 1 | 2013 | 130 | 0.110 |
Why?
|
| Cell-Free System | 1 | 2012 | 43 | 0.110 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2013 | 85 | 0.110 |
Why?
|
| Polyphenols | 2 | 2009 | 34 | 0.100 |
Why?
|
| Collagenases | 2 | 2009 | 34 | 0.100 |
Why?
|
| Physicians | 1 | 2015 | 324 | 0.100 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 179 | 0.100 |
Why?
|
| Endovascular Procedures | 1 | 2015 | 366 | 0.100 |
Why?
|
| Computed Tomography Angiography | 1 | 2015 | 424 | 0.100 |
Why?
|
| Cell Polarity | 1 | 2010 | 49 | 0.090 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 2 | 2007 | 16 | 0.090 |
Why?
|
| Pancreatic Elastase | 3 | 2005 | 33 | 0.090 |
Why?
|
| Antioxidants | 1 | 2012 | 304 | 0.090 |
Why?
|
| Bioreactors | 1 | 2010 | 65 | 0.090 |
Why?
|
| Coronary Vessels | 1 | 2013 | 313 | 0.090 |
Why?
|
| Indoles | 1 | 2010 | 146 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2010 | 124 | 0.090 |
Why?
|
| Cell Nucleus | 1 | 2010 | 305 | 0.090 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2007 | 126 | 0.090 |
Why?
|
| Nanotubes, Carbon | 1 | 2010 | 73 | 0.090 |
Why?
|
| Macrophages | 2 | 2010 | 647 | 0.090 |
Why?
|
| Inflammation Mediators | 2 | 2021 | 244 | 0.080 |
Why?
|
| Calcium Chloride | 2 | 2007 | 38 | 0.080 |
Why?
|
| Prostheses and Implants | 2 | 2007 | 159 | 0.080 |
Why?
|
| Gelatinases | 2 | 2010 | 12 | 0.080 |
Why?
|
| Temperature | 5 | 2007 | 340 | 0.080 |
Why?
|
| Microscopy, Electron, Scanning | 3 | 2018 | 236 | 0.080 |
Why?
|
| Bone Remodeling | 1 | 2007 | 45 | 0.080 |
Why?
|
| RANK Ligand | 1 | 2007 | 73 | 0.080 |
Why?
|
| Muscle, Smooth | 1 | 2007 | 117 | 0.070 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2007 | 48 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2007 | 88 | 0.070 |
Why?
|
| Bone Density | 1 | 2007 | 159 | 0.070 |
Why?
|
| Electrophoresis | 2 | 2007 | 69 | 0.070 |
Why?
|
| Neomycin | 1 | 2007 | 56 | 0.070 |
Why?
|
| Cell Line | 1 | 2010 | 1752 | 0.070 |
Why?
|
| Osteoclasts | 1 | 2007 | 132 | 0.070 |
Why?
|
| Dendrimers | 1 | 2005 | 12 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2006 | 102 | 0.070 |
Why?
|
| Intestine, Small | 1 | 2005 | 89 | 0.060 |
Why?
|
| Tunica Media | 1 | 2004 | 33 | 0.060 |
Why?
|
| Elastic Tissue | 1 | 2004 | 28 | 0.060 |
Why?
|
| Tenascin | 1 | 2004 | 39 | 0.060 |
Why?
|
| Blood Platelets | 1 | 2005 | 284 | 0.060 |
Why?
|
| Thrombosis | 1 | 2005 | 218 | 0.060 |
Why?
|
| Hydrolysis | 1 | 2003 | 144 | 0.060 |
Why?
|
| Chondroitinases and Chondroitin Lyases | 1 | 2003 | 6 | 0.060 |
Why?
|
| Phosphorus | 1 | 2003 | 64 | 0.060 |
Why?
|
| Cell Movement | 1 | 2005 | 630 | 0.050 |
Why?
|
| Cell Death | 1 | 2003 | 329 | 0.050 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2001 | 59 | 0.050 |
Why?
|
| Biomarkers | 2 | 2021 | 1593 | 0.050 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2021 | 135 | 0.050 |
Why?
|
| Sheep | 1 | 2020 | 128 | 0.050 |
Why?
|
| Mice, Knockout, ApoE | 1 | 2019 | 3 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 1293 | 0.050 |
Why?
|
| Hyperglycemia | 1 | 2021 | 158 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2020 | 1692 | 0.040 |
Why?
|
| Disease Management | 1 | 2021 | 248 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2020 | 100 | 0.040 |
Why?
|
| Tensile Strength | 2 | 2012 | 90 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 951 | 0.040 |
Why?
|
| Hemodynamics | 2 | 2019 | 705 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2019 | 199 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2021 | 384 | 0.040 |
Why?
|
| Lipids | 1 | 2019 | 298 | 0.040 |
Why?
|
| Female | 3 | 2020 | 38015 | 0.040 |
Why?
|
| Echocardiography | 1 | 2020 | 515 | 0.040 |
Why?
|
| Calorimetry, Differential Scanning | 2 | 2007 | 27 | 0.040 |
Why?
|
| Metalloendopeptidases | 1 | 1996 | 67 | 0.040 |
Why?
|
| Chromatography, Gel | 2 | 1993 | 79 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2019 | 631 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1993 | 272 | 0.030 |
Why?
|
| Patient-Specific Modeling | 1 | 2015 | 18 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2015 | 51 | 0.030 |
Why?
|
| Elasticity | 2 | 2005 | 103 | 0.030 |
Why?
|
| Alkaline Phosphatase | 2 | 2006 | 71 | 0.030 |
Why?
|
| Drug Combinations | 2 | 2007 | 304 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 330 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2007 | 682 | 0.030 |
Why?
|
| Apoferritins | 1 | 2013 | 6 | 0.030 |
Why?
|
| Horses | 1 | 2013 | 20 | 0.030 |
Why?
|
| Colorimetry | 1 | 1993 | 22 | 0.030 |
Why?
|
| Microscopy, Polarization | 1 | 1993 | 7 | 0.030 |
Why?
|
| Oxides | 1 | 2013 | 47 | 0.030 |
Why?
|
| Sutures | 1 | 1993 | 32 | 0.030 |
Why?
|
| Protease Inhibitors | 1 | 1993 | 76 | 0.030 |
Why?
|
| Serum Albumin | 1 | 1993 | 104 | 0.030 |
Why?
|
| Proteoglycans | 1 | 1993 | 103 | 0.030 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 373 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 621 | 0.030 |
Why?
|
| Shear Strength | 1 | 2012 | 15 | 0.030 |
Why?
|
| Mice | 2 | 2020 | 8472 | 0.030 |
Why?
|
| Glycation End Products, Advanced | 1 | 2012 | 125 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1465 | 0.030 |
Why?
|
| Iron | 1 | 2013 | 197 | 0.030 |
Why?
|
| Lysine | 1 | 1991 | 96 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 1993 | 1082 | 0.020 |
Why?
|
| Acid Phosphatase | 1 | 2010 | 36 | 0.020 |
Why?
|
| Sarcomeres | 1 | 2010 | 32 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 1446 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2010 | 71 | 0.020 |
Why?
|
| Mechanical Phenomena | 1 | 2010 | 21 | 0.020 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2010 | 74 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2010 | 144 | 0.020 |
Why?
|
| Anisotropy | 1 | 2010 | 105 | 0.020 |
Why?
|
| Biotin | 1 | 2010 | 28 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 254 | 0.020 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2010 | 72 | 0.020 |
Why?
|
| Solubility | 1 | 2010 | 134 | 0.020 |
Why?
|
| Surface Plasmon Resonance | 1 | 2010 | 50 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2077 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2010 | 85 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2010 | 144 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 337 | 0.020 |
Why?
|
| Gold | 1 | 2010 | 76 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 492 | 0.020 |
Why?
|
| Nanotechnology | 1 | 2010 | 109 | 0.020 |
Why?
|
| Surface Properties | 1 | 2010 | 363 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2020 | 7028 | 0.020 |
Why?
|
| Osteoprotegerin | 1 | 2007 | 11 | 0.020 |
Why?
|
| Kinetics | 2 | 2004 | 1047 | 0.020 |
Why?
|
| Phenotype | 1 | 2010 | 946 | 0.020 |
Why?
|
| Protein Denaturation | 1 | 2007 | 27 | 0.020 |
Why?
|
| Sepharose | 1 | 2007 | 18 | 0.020 |
Why?
|
| Cathepsin K | 1 | 2007 | 16 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2007 | 111 | 0.020 |
Why?
|
| Periodic Acid | 1 | 2006 | 5 | 0.020 |
Why?
|
| Cell Transplantation | 1 | 2007 | 22 | 0.020 |
Why?
|
| Carbodiimides | 1 | 2006 | 6 | 0.020 |
Why?
|
| Hexosamines | 1 | 2006 | 10 | 0.020 |
Why?
|
| Cathepsins | 1 | 2007 | 37 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2007 | 137 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2007 | 175 | 0.020 |
Why?
|
| Tretinoin | 1 | 2007 | 92 | 0.020 |
Why?
|
| Drug Stability | 1 | 2006 | 71 | 0.020 |
Why?
|
| Sialoglycoproteins | 1 | 2006 | 24 | 0.020 |
Why?
|
| Osteopontin | 1 | 2006 | 28 | 0.020 |
Why?
|
| Cytokines | 1 | 2010 | 866 | 0.020 |
Why?
|
| Cholecalciferol | 1 | 2007 | 143 | 0.020 |
Why?
|
| Transplants | 1 | 2005 | 28 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2006 | 155 | 0.020 |
Why?
|
| Aneurysm | 1 | 2005 | 53 | 0.020 |
Why?
|
| Organ Preservation Solutions | 1 | 2005 | 45 | 0.020 |
Why?
|
| Desmosine | 1 | 2004 | 4 | 0.020 |
Why?
|
| Capillary Permeability | 1 | 2004 | 69 | 0.020 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2004 | 24 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2006 | 397 | 0.020 |
Why?
|
| Astringents | 1 | 2004 | 2 | 0.020 |
Why?
|
| Aluminum Compounds | 1 | 2004 | 10 | 0.020 |
Why?
|
| Chlorides | 1 | 2004 | 68 | 0.020 |
Why?
|
| Biodegradation, Environmental | 1 | 2004 | 92 | 0.020 |
Why?
|
| Gene Expression | 1 | 2007 | 770 | 0.020 |
Why?
|
| Skin | 1 | 2007 | 451 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 201 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 765 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 189 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2004 | 223 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2004 | 324 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 1037 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2006 | 384 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2015 | 7264 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 371 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 954 | 0.010 |
Why?
|
| Heart | 1 | 2006 | 850 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2004 | 1173 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2004 | 938 | 0.010 |
Why?
|
| Methods | 1 | 1995 | 156 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 1995 | 87 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 1991 | 43 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1995 | 1615 | 0.000 |
Why?
|
| Adolescent | 1 | 1995 | 8903 | 0.000 |
Why?
|
| Middle Aged | 1 | 1995 | 21119 | 0.000 |
Why?
|
| Adult | 1 | 1995 | 21375 | 0.000 |
Why?
|